Organovo Holdings Inc (NYSEMKT:ONVO) Shares Gain By 2.00%


Dallas, Texas 11/19/2013 (Financialstrend) – In Monday’s trading session, Organovo Holdings Inc (NYSEMKT:ONVO) rose by 2.00%. The shares opened at a price of $13.04, which touched the intraday high of $13.65 and headed to a close of $12.75. Around 17.50 million exchanged hands over the trading day and an average volume of 5.38 million shares were traded over a 30 day period. The 52-week low of Organovo Holdings Inc (NYSEMKT:ONVO) shares is $1.80 and its 52-week high is $13.65. The company has a market capitalization of $975.47 million.                                        

About the company

Organovo Holdings Inc (NYSEMKT:ONVO) was previously Real Estate Restoration & Rental. It was formed in 2007 and is a development stage company. It has developed & is commercializing a platform-technology for generation of three-dimensional human-tissues. These tissues can be employed in drug-discovery & development, biological-research & as therapeutic-implants for treating damaged / degenerating tissues & organs.

On 28th  December 2011, Real Estate Restoration & Rental, Inc. entered into an Agreement & Plan of Merger, after to which RERR merged with the 100%-owned subsidiary-  Organovo. On 8th February 2012, Organovo Holdings Inc (NYSEMKT:ONVO) merged with &  into Organovo Acquisition Corp a 100%-owned subsidiary of Organovo, with it surviving this merger as a 100%-owned subsidiary of Organovo Holdings (the Merger). As a result of this Merger, Organovo Holdings Inc (NYSEMKT:ONVO)  acquired the business of Organovo, Inc.

It  has collaborative research-agreements with Pfizer, Inc &  United Therapeutic Corporation. As of 31st March 2012, Organovo Holdings Inc (NYSEMKT:ONVO) has 5 federal grants. These include small-business Innovation Research grants & developed the NovoGen MMX-Bioprinter. This was the company’s 1st -generation 3D bioprinter. Organovo Holdings Inc (NYSEMKT:ONVO) is involved in developing specific 3D human-tissues to help Pfizer in discovering f therapies in 2 areas of interest. In addition to this, in 2011 October, the company entered into a research-agreement with Unither to establish & conduct a research-program to discover the treatments for pulmonary-hypertension using the  NovoGen MMX Bioprinter technology.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.